Answers are grounded in this paper and cite their sources.
Our data showed high inter-laboratory variability in the assessment of HER2-low breast cancer. The findings cast doubt on whether the current test method for HER2 is robust and reliable enough to select HER2-low patients for HER2-targeted treatment in daily clinical practice.
No takes yet. Share an insight, caveat, or question.
Nielsen et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: